Skip Navigation



JAC Advance Access published online on June 2, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl240
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/2/432    most recent
dkl240v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Galani, I.
Right arrow Articles by Giamarellou, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galani, I.
Right arrow Articles by Giamarellou, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received February 8, 2006
Revised May 15, 2006
Accepted May 15, 2006

Brief report

Molecular characterization of an Escherichia coli clinical isolate that produces both metallo-{beta}-lactamase VIM-2 and extended-spectrum {beta}-lactamase GES-7: identification of the In8 integron carrying the blaVIM-2 gene

Irene Galani 1, Maria Souli 1, Evangelos Koratzanis 1, Zoi Chryssouli 1, and Helen Giamarellou 1 *

1 4th Department of Internal Medicine, Molecular Biology Section, University General Hospital ‘ATTIKON’, Rimini 1, 124 62 Chaidari, Greece

* To whom correspondence should be addressed.
Helen Giamarellou, E-mail: hgiama{at}ath.forthnet.gr


  Abstract

Objectives: We have previously reported the isolation of a VIM-2-producing Escherichia coli clinical isolate and the coexistence of blaVIM-2 and blaGES-7 in the same isolate. The aim of this study was to elucidate the genetic environment of these genes.

Methods: PCR and sequence analysis were used to identify and analyse the blaVIM-containing integron. The location of the blaVIM-2 and blaGES-7 genes was identified by hybridization experiments on I-CeuI-digested genomic DNA after PFGE.

Results: Only the blaVIM-2 gene has been found on a class I integron, designated In8 (1474 bp). Hybridization with the blaVIM-2, the blaGES-7 and the 16S-23S rRNA probes confirmed the chromosomal location of both genes. The blaVIM-2 probe hybridized with a 710 kb fragment whereas the blaGES-7 probe hybridized with a 144 kb fragment of genomic DNA of the E. coli isolate.

Conclusions: This report provides evidence for the chromosomal location of both blaVIM-2 and blaGES-7 genes carried by an E. coli clinical isolate. In8, containing blaVIM-2, presents an emerging threat of carbapenem resistance among E. coli isolates in Greece.

Keywords: E. coli; blaVIM-2; blaGES-7.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. Walther-Rasmussen and N. Hoiby
Class A carbapenemases
J. Antimicrob. Chemother., September 1, 2007; 60(3): 470 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Ikonomidis, M. Labrou, Z. Afkou, A. N. Maniatis, D. Sofianou, A. Tsakris, and S. Pournaras
First Occurrence of an Escherichia coli Clinical Isolate Producing the VIM-1/VIM-2 Hybrid Metallo-{beta}-Lactamase VIM-12
Antimicrob. Agents Chemother., August 1, 2007; 51(8): 3038 - 3039.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.